Abstract
Large cartilage defects in the knee are debilitating for patients and challenging for surgeons to treat. Autologous chondrocyte implantation (ACI) has gained popularity over the past 20 years and has become the treatment of choice for large cartilage defects for some surgeons. Termed matrix-applied ACI (MACI), use of autologous chondrocytes cultured on porcine collagen membrane has recently been approved by the U.S. Food and Drug Administration for the treatment of symptomatic full-thickness cartilage defects in the knee. This new technique for cartilage repair is the third generation of chondrocyte implantation technology and the first to involve the use of a scaffolding to grow chondrocytes1. MACI is a simpler technique than previous generations and has more reliable chondrocyte seeding. Research has shown that patients do well postoperatively, with improvements in patient-reported outcome out to 5 years postoperatively3. These improvements are statistically greater for patients who underwent MACI when compared to those who underwent microfracture2. (1) Preoperative evaluation: patients are indicated for a cartilage procedure after magnetic resonance imaging (MRI) and clinical examination. (2) Stage 1: a diagnostic arthroscopy is performed, and chondrocytes are harvested and cultured. (3) Approach: a short vertical incision is made, followed by a medial parapatellar arthrotomy. (4) Debridement: the lesion is identified and debrided back to stable cartilage. (5): Hemostasis: hemostasis is obtained with an epinephrine-soaked sponge. (6) Template creation: foil is used to create a template of the lesion. (7) Cells cutting: with use of the foil, the membrane of cells is cut to the appropriate size and shape. (8) Implantation: the cut membrane is placed on the lesion and secured with fibrin glue. (9) Testing: the knee is taken through a range of motion and the stability of the membrane is confirmed. (10) Closure: standard closure in layers is performed.
Footnotes
Published outcomes of this procedure can be found at: Am J Sports Med. 2014 Jun;42(6):1384-94.
Disclosure: There was no external funding for this study. On the Disclosure of Potential Conflicts of Interest forms, which are provided with the online version of the article, one or more of the authors checked “yes” to indicate that the author had a relevant financial relationship in the biomedical arena outside the submitted work (http://links.lww.com/JBJSEST/A228).
References
- 1.U.S. Food and Drug Administration. FDA approves first autologous cellularized scaffold for the repair of cartilage defects of the knee. 2016. December 13 https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533153.htm. Accessed 2018 Jul 20.
- 2.Basad E, Wissing FR, Fehrenbach P, Rickert M, Steinmeyer J, Ishaque B. Matrix-induced autologous chondrocyte implantation (MACI) in the knee: clinical outcomes and challenges. Knee Surg Sports Traumatol Arthrosc. 2015. December;23(12):3729-35. Epub 2014 Sep 14. [DOI] [PubMed] [Google Scholar]
- 3.Saris D, Price A, Widuchowski W, Bertrand-Marchand M, Caron J, Drogset JO, Emans P, Podskubka A, Tsuchida A, Kili S, Levine D, Brittberg M; SUMMIT Study Group. Matrix-applied characterized autologous cultured chondrocytes versus microfracture: two-year follow-up of a prospective randomized trial. Am J Sports Med. 2014. June;42(6):1384-94. Epub 2014 Apr 8. [DOI] [PubMed] [Google Scholar]